| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8735677 | Journal of Clinical and Experimental Hepatology | 2018 | 8 Pages |
Abstract
Sofosbuvir plus daclatasvir, with or without ribavirin achieved high efficacy and safety in HCV genotype 4 patients. Their effects were accompanied with attenuation of liver fibrosis. Further wider-scale studies are needed to evaluate the actual role of IL18 polymorphisms in treatment response with sofosbuvir/daclatasvir.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hepatology
Authors
Asmaa M. Abdel-Aziz, Mohamed A. Ibrahim, Azza A. El-Sheikh, Maha Y. Kamel, Nagwa M. Zenhom, Salam Abdel-Raheim, Hisham Abdelhaleem,